SCHEMBL3843948

SCHEMBL3843948

Cc1ccc(-c2nn(Cc3ccc([N+](=O)[O-])cc3)c3ccccc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 1/20 0.53
LMNA P02545 2/20 0.51
P2RX4 Q99571 1/20 0.49
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 5/20 0.47
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
CFTR P13569 1/20 0.47
CNR1 P21554 1/20 0.46
ACHE P22303 1/20 0.46
CNR2 P34972 1/20 0.46
PDE5A O76074 1/20 0.46
MITF O75030 1/20 0.45
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
THRB P10828 1/20 0.44
RORC P51449 1/20 0.44
AURKA O14965 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478716 0.88 F2RL3 (0.60) F2RL3LMNAP2RX4KMT2AALDH1A1
SCHEMBL13618343 0.84 F2RL3 (0.66) F2RL3LMNAKMT2AALDH1A1MAPT
SCHEMBL4483522 0.83 CYP1A2 (0.56) F2RL3LMNAP2RX4KMT2AMEN1
SCHEMBL14290280 0.82 RAB9A (0.53) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL27669280 0.82 F2RL3 (0.55) F2RL3LMNAP2RX4KMT2AALDH1A1
SCHEMBL4478119 0.80 CNR2 (0.59) F2RL3LMNAKMT2AMEN1ALDH1A1
SCHEMBL3840013 0.76 MAPT (0.57) F2RL3LMNAKMT2AMEN1ALDH1A1
SCHEMBL20379747 0.76 L3MBTL1 (0.71) LMNAP2RX4KMT2AMEN1ALDH1A1
SCHEMBL5443540 0.76 CNR2 (0.55) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL28429765 0.75 MCL1 (0.65) LMNAKMT2AMAPTSMN1; SMN2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1425011-B1 ENHANCEMENT OF LEARNING AND MEMORY AND TREATMENT OF AMNESIA CARLSBAD TECHNOLOGY INC (US) 2009-11-04 EP disclosed
EP-1425011-B1 ENHANCEMENT OF LEARNING AND MEMORY AND TREATMENT OF AMNESIA CARLSBAD TECHNOLOGY INC (US) 2009-11-04 EP disclosed
US-7049334-B2 Enhancement of learning and memory and treatment of amnesia CARLSBAD TECHNOLOGY, INC. (US) 2006-05-23 US disclosed
CN-1254241-C Use of fused ring pyrazole compounds for the preparation of medicaments for enhancing learning and memory and for the treatment of amnesia CARLSBAD TECHNOLOGY INC (US) 2006-05-03 CN disclosed
CN-1585637-A Enhancement of learning and memory and treatment of amnesia CARLSBAD TECHNOLOGY INC (US) 2005-02-23 CN disclosed
US-20030105149-A1 Enhancement of learning and memory and treatment of amnesia CARLSBAD TECHNOLOGY, INC. 2003-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105149-A1 Enhancement of learning and memory and treatment of amnesia NR1H3, NR1H2, RORA F2RL3 766/4885LMNA 3592/4885P2RX4 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.